» Articles » PMID: 31686862

Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2019 Nov 6
PMID 31686862
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: PTC is not generally considered a lethal disease, but prone to recurrence as the prognosis. Hashimoto's thyroiditis (HT) is an important factor that affects the prognosis of papillary thyroid carcinoma (PTC). It is crucial to find biomarkers to identify the combination of HT with PTC and to predict the prognosis.

Methods: RNASeq data from the Cancer Genome Atlas (TCGA) database was used to screen differentially expressed genes (DEGs) of PTC with HT via the edgeR package of R software version 3.3.0. Also, the DEGs were applied to the DAVID web-based tool to determine the enrichment of gene functions via Gene Ontology (GO) analysis and to identify associated pathways in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. By constructing protein interaction networks within Cytoscape software, we screened candidate genes and explored possible relationships with the clinical phenotype of PTC. Finally, additional thyroid tissue samples were collected to verify the results above.

Results: After analyzing the RNA-Seq data of PTC patients from the Cancer Genomic Atlas, 497 differentially expressed PTC genes were found to be associated with HT, of which protein tyrosine phosphatase receptor type C (PTPRC), KIT, and COL1A1 were associated with tumor size and lymph node metastasis (p < 0.05). Verification of these results with another 30 thyroid tissues of clinical PTC patients revealed that the expression level of PTPRC in the PTC with HT group was higher than that in the PTC without HT group (p < 0.05) and the ROC curve showed a good discrimination (area under the curve = 0.846). However, the correlation with the clinical phenotype was not statistically significant (p > 0.05).

Discussion: These data suggest that upregulation of PTPRC enhances the incidence of HT associated with PTC and is also predictive of a poor prognosis.

Citing Articles

Therapeutic Potential of CRISPR/Cas in Hashimoto's Thyroiditis: A Comprehensive Review.

Upreti A, Mukherjee S Curr Gene Ther. 2024; 24(3):179-192.

PMID: 38310457 DOI: 10.2174/0115665232266508231210154930.


Identification and Interaction Analysis of Molecular Markers in Pancreatic Ductal Adenocarcinoma by Bioinformatics and Next-Generation Sequencing Data Analysis.

Giriyappagoudar M, Vastrad B, Horakeri R, Vastrad C Bioinform Biol Insights. 2023; 17:11779322231186719.

PMID: 37529485 PMC: 10387711. DOI: 10.1177/11779322231186719.


Meta-Analysis of Esophageal Cancer Transcriptomes Using Independent Component Analysis.

Ashenova A, Daniyarov A, Molkenov A, Sharip A, Zinovyev A, Kairov U Front Genet. 2021; 12:683632.

PMID: 34795689 PMC: 8594933. DOI: 10.3389/fgene.2021.683632.

References
1.
Li X, Abdel-Mageed A, Kandil E . BRAF mutation in papillary thyroid carcinoma. Int J Clin Exp Med. 2012; 5(4):310-5. PMC: 3443896. View

2.
Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari S . Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab. 2007; 92(4):1485-90. DOI: 10.1210/jc.2006-1571. View

3.
Cirello V, Recalcati M, Muzza M, Rossi S, Perrino M, Vicentini L . Fetal cell microchimerism in papillary thyroid cancer: a possible role in tumor damage and tissue repair. Cancer Res. 2008; 68(20):8482-8. DOI: 10.1158/0008-5472.CAN-08-0672. View

4.
Shi Y, Su C, Hu H, Yan H, Li W, Chen G . Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma. PLoS One. 2018; 13(6):e0198896. PMC: 6021053. DOI: 10.1371/journal.pone.0198896. View

5.
Jensen K, Patel A, Hoperia V, Larin A, Bauer A, Vasko V . Dynamic changes in E-cadherin gene promoter methylation during metastatic progression in papillary thyroid cancer. Exp Ther Med. 2012; 1(3):457-462. PMC: 3445881. DOI: 10.3892/etm_00000071. View